Can whole genome sequencing replace AST?

Similar documents
The role of PHE s AMRHAI Reference Unit

Consultation on Report from the EUCAST Subcommittee on the Role of Whole Genome Sequencing (WGS) in Antimicrobial Susceptibility Testing of Bacteria

by author ESCMID Online Lecture Library Implementation of EUCAST antimicrobial susceptibility testing methods Gunnar Kahlmeter, Derek Brown

Combatting AMR: diagnostics

Genomics and its Impact on Diagnostic Microbiology

Overview of EURL-AMR and NGS activities

International harmonization of breakpoints is it possible? Gunnar Kahlmeter EUCAST, CLSI

Sequence quality: GMI Proficiency Tests for Whole Genome Sequencing of bacteria

Susceptibility testing methods used in Europe Does it make a difference?

Voriconazole and Aspergillus spp. Rationale for the EUCAST clinical breakpoints, version May 2012

ESCMID Online Lecture Library. by author

ESCMID Online Lecture Library. by author

Colistin resistance Lyngby, DK, April 4, Dik Mevius, Wageningen Bioveterinary Research (CVI- Lelystad)

Quality Control and Quality Assurance for Antibiotic Testing

SonoSteam. Hanieh Musavian, SonoSteam FORCE Technology. Teknologi der kun anvender damp-ultralyd, derfor ingen kemi.

Standard Operating Procedure

National Center for Emerging and Zoonotic Infectious Diseases The Role of Breakpoint Committees for New Drugs Perspectives from the United States

Molecular susceptibility testing

Use of Molecular Assays for Resistance Detection

Rapid Diagnostic Tests for Antimicrobial Resistance: Comparability of Results and Interpretation of Data

What Are We Trying to Say Here? Standardizing Next Generation Sequencing Reports for Tuberculosis

The implementation and application of Whole Genome Sequencing in the Campylobacter Reference Laboratory at Public Health England Craig Swift

Setting Clinical Breakpoints/ECOFFS

NordicAST Bacteroides AST Study 2018

A year in clinical bioinformatics

Challenges and opportunities for whole genome sequencing based surveillance of antibiotic resistance

The interplay between AMR surveillance and science Report of JPIAMR workshop October 2016, The Research Council of Norway, Oslo, Norway

Critical analysis of available data on use of antibiotics in aquaculture

Antibiotic Resistance Genes: From The Farm To The Human Gut

generated by the usage of antimicrobial drugs is absent. She is the author of 14 publications in international journals.

Antimicrobial Resistance Prediction Using Deep Convolutional Neural Networks on Whole Genome Sequencing Data

Comments on Use of Databases for Establishing the Clinical Relevance of Human Genetic Variants

Empfindlichkeitstestung bei Pilzen Neuigkeiten? Bericht aus einem EUCAST AFST (yeasts and moulds) Netzwerk-Laboratorium

BSAC Susceptibility Testing Residential Workshop

Adopting EUCAST breakpoints in countries currently on CLSI breakpoints

Introduction to Whole Genome Sequencing and its Applications in Microbial Diagnostics

Disruptive Technology to Guide Precision Antibiotic Therapy

NDA Requirements: Surveillance, Clinical Trial Data, Breakpoints

Whole Genome Sequence Data Quality Control and Validation

Cut-off Values and Species-Specific Breakpoints 12/19/2016

Using Galaxy for the analysis of NGS-derived pathogen genomes in clinical microbiology

Scottish Microbiology & Virology Network (SMVN)

CORPORATE PRESENTATION

CARBAPENEM-RESISTANT ENTEROBACTERIACEAE (CRE) LABORATORY CAPACITY SURVEY. Summary Data Report

Genomic Research: Issues to Consider. IRB Brown Bag August 28, 2014 Sharon Aufox, MS, LGC

Identifying Bacteriophages in Metagenomic Data Sets

Hosted by Paul Webber page 1

9th National Conference on the Laboratory Aspects of Tuberculosis

A Verification Study for Implementing the Revised CLSI Breakpoints. Summary. Breakpoint Differences Cephalosporin Breakpoints for Enterobacteriaceae

Abstract. Introduction

A Verification Study for Implementing the Revised CLSI Breakpoints. Summary. Glossary CDC 1

ANTIMICROBIAL SUSCEPTIBILITY TESTING: ADVANCED

by author How to effectively report laboratory findings to clinicians (Breakpoints and Interpretation)

Carbapenem-resistant Enterobacteriaceae (CRE): Surveillance and Response. David Selvage, MHS, PA-C New Mexico Department of Health March 15, 2016

Forecast diagnostics for antimicrobial resistance (AMR)

Investigational New Drug - Groundwork for in vitro antimicrobial susceptibility testing

Antimicrobial Susceptibility Testing

Antimicrobial Susceptibility Testing - How far are we from international consensus?

ND4BB Topic 3: Discovery and development of new drugs combatting Gram-negative infections

Open-access antimicrobial drug discovery BIO 2016

Open-access antimicrobial drug discovery BIO 2016

GMI: Global Microbial Identifier

Metallo-β-lactamase (MBL) project: From molecular biology to the development of an MBL-inhibitor

PERANAN MIKROBIOLOGI DALAM DIAGNOSIS PENYAKIT INFEKSI. dr. Agus Eka Darwinata, Ph.D.

Elena BM Breidenstein, PhD 21 April 2018

3/19/2016. Disclaimer. Defense, or U.S. Government. The authors have no conflict of interest to report.

Verification of Disk Diffusion Tests

Pharmacogenomics within the EHR

Curriculum Vitae. Abbas Maleki, Ph.D. Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran

The Antimicrobial Resistance Laboratory Network (ARLN) Providing CRE Colonization Testing to a State Lab in a Neighboring Region June 4, 2018

12 th EURL-AR Workshop

2016 EUROPE NORDIC U.S. SYMPOSIUM. New Frontiers in Antibacterial Resistance Research. Karolinska Institute. Stockholm

Precision. Proficiency. Proximity.

Next generation sequencing in diagnostic laboratories: opportunities and challenges

Mycobacterium tuberculosis and Drug- Resistance Testing

IMPLEMENTATION OF EUCAST BREAKPOINTS

Antimicrobial Susceptibility Testing Method User Day

Inside the Burch Lab: E. Coli and Triclosan Resistance. By: Pamela Lammonds

Cloning and Characterization of E. meningoseptica Beta Lactamase

The ENABLE project: An antibiotic discovery platform

Verification of Gradient Diffusion Strips

Beef Industry Safety Summit Renaissance Austin Hotel 9721 Arboretum Blvd. Austin, TX March 1-3

DNBseq TM SERVICE OVERVIEW Plant and Animal Whole Genome Re-Sequencing

Enabling the adoption of new diagnostics within the UK healthcare system:

Whole genome sequencing in the reference laboratory: An Introduction & Overview

Whole Genome Sequencing for Enteric Pathogen Surveillance and Outbreak Investigations

Environmental Surveillance FIDSSA Dr Ben Prinsloo Medical Microbiologist

The 100,000 Genomes Project Genomics Collaboration Event Finnish Residence

Real world applications of whole genome sequencing. Henrik Hasman Bacteria, parasites and fungi Statens Serum Institut, Denmark

Whole-Genome Sequencing (WGS) for Food Safety

CPTR title slide. Daniela M Cirillo San Raffaele Scientific Institute NDWG-Cochair

ISO 15189:2012 and Susceptibility Testing BSAC User Day 22 June 2016

UK AMR Diagnostics Collaborative:

Pathogenic bacteria replicate and persevere in ecological niches called reservoirs

Shionogi Presents Results of the First Clinical Efficacy Trial and In Vitro Data on Cefiderocol (S ), a Siderophore Cephalosporin

Dr. Rukumani Devi Velayuthan Mycology Unit Co-ordinator PPUM

ENABLE (IMI) presentation of activities

Screening for Resistant Organisms and Infection Control

Zacks Small-Cap Research

Evolution of Next Generation Sequencing Technology: Ready for Patient Management?

Transcription:

Can whole genome sequencing replace AST? Matthew J Ellington Antimicrobial Resistance & Healthcare Associated Infections (AMRHAI) Reference Unit Crown copyright

EUCAST Subcommittee on the role of whole genome sequencing (WGS) in AST of bacteria 1. Review literature describing the role of WGS in AST of bacteria 2. Assess the sensitivity and specificity of WGS vs phenotypic AST 3. Consider how WGS for AST may be applied in clinical micro labs Likely implications for pheno and other geno methods in use 4. Consider the epidemiological implications of using WGS 5. Consider the clinical implications of WGS for the selection of R x 6. Consider the principles of how the results of WGS for AST could be presented to clinical users to describe the drivers and barriers to routine use of WGS Report out for consultation http://www.eucast.org/documents/consultations/ 2 RaMi-NGS, 10 th June 2016 Crown Copyright

What can WGS offer? Measures susceptibility Resistance mechanisms ECOFF (WT vs. non-wt) Clinical resistance (S vs. R) Additional data Suitable speed Cost Phenotypic AST (limited) (most) (e.g. TB) WGS-based AST? (must be inferred) (most) (e.g. TB) 3 RaMi-NGS, 10 th June 2016 Crown Copyright

Most appropriate AST comparators What criteria should WGS data be assessed against? clinical breakpoints indicate likelihood of therapeutic success (S) or failure (R) of antibiotic treatment based on microbiological findings ECOFFs (epidemiological cut-off values) differentiate wild-type (WT) from nonwild-type (NWT) isolates with an acquired resistance mechanism 4 RaMi-NGS, 10 th June 2016 Crown Copyright

Focus on WHO priority organisms Organisms Enterobacteriaceae E. coli 3GC, FQs Priority resistances K. pneumoniae 3GC, carbapenems Non-typhoidal Salmonella Shigella spp. FQs FQs S. aureus - MRSA S. pneumoniae - Penicillin N. gonorrhoeae - 3GCs Plus others M. tuberculosis, C. difficile, A. baumannii, P. aeruginosa 5 RaMi-NGS, 10 th June 2016 Crown Copyright

A growing literature 501 isolates; S. aureus; 5112 143 AST isolates;2 results; 98.8% species; WGS 1001 concordance AST results; 96.7% WGS concordance 388 isolates; 1 species; 1158 AST results; 88.9% WGS concordance 6 RaMi-NGS, 10 th June 2016 Crown Copyright

Evidence reports e.g. Enterobacteriaceae The relatively limited number of acquired resistance genes and resistanceassociated mutations that dominate epidemiologically in the Enterobacteriaceae High levels of accuracy of genotype-phenotype correlation in published studies; means that well-informed screening approaches can be very accurate. Predicting AST results will be harder for some than for others to improve the levels of accuracy across large genetically diverse datasets we need to understand more of: The full range of mechanisms + better detection of unknowns (e.g. mcr-1) Interplay between mechanisms 7 RaMi-NGS, 10 th June 2016 Crown Copyright

Complex interplays determine an MIC External [drug] V Entry + V Efflux Periplasmic [drug] V Hydrolysis V Binding It s a lot more complex than gene presence / absence 8 RaMi-NGS, 10 th June 2016 Crown Copyright

Combinatorial resistance: WGS vs. AST 9 RaMi-NGS, 10 th June 2016 Crown Copyright Reuter, Ellington, Cartwright et al., 2013. JAMA Intern Med 12;173:1397-404

Non-organism based factors (1) Data quality Before WGS can be routinely implemented into accredited clinical practice there is a need to establish necessary minimum QC-thresholds Currently there are no international QC standards GMI driving WGS proficiency testing project with 50 laboratories worldwide Such initiatives are important first steps towards setting QC thresholds 10 RaMi-NGS, 10 th June 2016 Crown Copyright

Non-organism based factors (2) AMR gene database: A single, standardised reference db Need better standardisation of annotation of AMR genes Will help improve accuracy in public databases Need a single, regularly updated challenge database containing all validated AMR genes and chromosomal SNPs linked with AMR Minimum standards for including new determinants in the standard db Need international consensus on criteria to define novel or variant genes Inextricably linked to issues of gene nomenclature 11 RaMi-NGS, 10 th June 2016 Crown Copyright

Non-organism based factors (3) Systematic sources of error for pheno / geno correlation Flaws with phenotypic AST An inadequate limit of detection of WGS i.e. when detection is direct from clinical specimens e.g. TB Incomplete knowledge base for genotypic basis of phenotypic resistance Affects sensitivity of WGS prediction (resulting in very major errors) In development phase - anticipate many gaps in the knowledge-base problematic bacteria; problematic antibiotics 12 RaMi-NGS, 10 th June 2016 Crown Copyright

Impacts (incl. clinical) of WGS-based genotypic AST Further evidence needed, but could soon replace much surveillance AST low impact of the low error rate Further evidence needed, but could soon reduce AST tests in reference labs unless to guide treatment for agents with poorest genotypic/phenotypic concordance comparative in-vitro activity of new agents longer for a paradigm shift to WGS to guide clinical decision making very major errors - gene absence cannot always predict susceptibility robust evidence will be needed surveillance of treatment failure +/- novel resistance mechanisms education needed and major behavioural change for prescribers 13 RaMi-NGS, 10 th June 2016 Crown Copyright

Concluding comments Currently: insufficient data to present a definitive document on the topic Review describes current state-of-the art and will require updates Quantity / quality of evidence for pheno/geno concordance must improve An MIC reflects more than gene presence / absence: ECOFFs first comparator, breakpoints will be tougher but are necessary Algorithms vary, but for comparisons they: should use the same centralised database of loci should have been calibrated and shown equivalent Advocating a global standard method is unrealistic at this time Learn lessons from the past and avoid multiple parallel routine systems Balance need to standardise with academic drivers for bioinformaticians to develop and improve their own tools 14 RaMi-NGS, 10 th June 2016 Crown Copyright

Acknowledgements & live consulatation Gunnar Kahlmeter and Derek Brown for setting the challenge Committee members for excellent contributions and discussions: Frank M. Aarestrup (Denmark) Rafael Canton (Spain) Michel Doumith (UK) Oskar Ekelund (Sweden, co-editor) Christian Giske (Sweden) Hajo Grundman (Germany) Henrik Hasman (Denmark) Katie L. Hopkins (UK) Matt Holden (UK) Jon Iredell (Australia) Gunnar Kahlmeter (Sweden) Claudio U. Koser (UK) Alasdair MacGowan (UK) Dik Mevius (Netherlands) Mike Mulvey (Canada) Thierry Naas (France) Tim Peto (UK) Jean-Marc Rolain (France) Ørjan Samuelsen (Norway) Neil Woodford (UK, Chair) Report for comment: http://www.eucast.org/documents/consultations/ 15 RaMi-NGS, 10 th June 2016 Crown Copyright